InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting
June 01 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced the posting of the management presentation and Q&A
session recording from the 2017 Annual Shareholders Meeting held on
May 30th, 2017. The recording is available on the investor
relations page of InVivo’s website at
http://www.invivotherapeutics.com/investor-relations/annual-meeting/.
Mark Perrin, Chief Executive Officer and Chairman, said, “I was
pleased with the turnout at this year’s annual shareholders
meeting. The meeting was a great opportunity for me to answer
questions directly from our shareholders while providing some key
updates on our recent progress. I look forward to continued
opportunities to communicate with the investment community going
forward.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as "believe," "anticipate,"
"intend," "estimate," "will," "may," "should," "expect," “designed
to,” “potentially,” and similar expressions, and include statements
regarding the HDE approval process, the expected impact of the
Contemporary Thoracic SCI Cohort Study on clinical and regulatory
timelines and the likelihood of demonstration of safety and
probable benefit. Any forward-looking statements contained herein
are based on current expectations, and are subject to a number of
risks and uncertainties. Factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
company’s ability to successfully open additional clinical sites
for enrollment and to enroll additional patients; the timing of the
Institutional Review Board process; the company’s ability to
complete The INSPIRE Study, submit an HDE application, and receive
regulatory approval for the Neuro-Spinal Scaffold, the company’s
ability to commercialize its products; the company’s ability to
develop, market and sell products based on its technology; the
expected benefits and efficacy of the company’s products and
technology in connection with the treatment of spinal cord
injuries; the availability of substantial additional funding for
the company to continue its operations and to conduct research and
development, clinical studies and future product commercialization;
and other risks associated with the company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies identified and described in more
detail in the company’s Quarterly Report of the three months ended
March 31, 2017, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company
does not undertake to update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601005705/en/
InVivo Therapeutics Holdings Corp.Heather Hamel,
617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024